IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Cannabis Law Report
JUNE 7, 2021
To IGC’s knowledge, this is the first human clinical trial using low doses of natural THC, a psychoactive member of the cannabinoid class of natural products produced by the Cannabis sativa plant, on Alzheimer’s patients. As the disease progresses, individuals may suffer from loss of memory and dementia.
Let's personalize your content